The recent shift in U.S. vaccination guidance has raised significant concern among clinicians and researchers. The Advisory Committee on Immunization Practices voted 8–3 to halt routine hepatitis B immunization at birth despite more than 40 years of robust data supporting the practice. The decision immediately changed long-standing national policy affecting newborns across the United States.
The committee provided no new evidence to justify delaying the first dose to two months of age. Leading infectious-disease specialists warned that the move increases risk during the earliest and most vulnerable stage of life. In response to the meeting, researchers highlighted extensive historical data confirming that the birth dose is both safe and effective.
Table of contents:
- Cody Meissner and the revised birth-dose policy
- José Romero, global policies and the evidence base
- Hepatitis B risk in U.S. households and the role of early immunization
- Su Wang and the consequences of delayed protection
Broader scientific context on immune responses can be found in this overview.
Cody Meissner and the revised birth-dose policy
The altered recommendation limits the first dose of the hepatitis B vaccine to infants born to mothers who test positive for the virus. For mothers who test negative, ACIP now advises postponing the initial dose until infants reach two months of age. No scientific evidence supporting this timing change was presented during the meeting.
Cody Meissner, a pediatric infectious disease specialist and one of the few ACIP members with direct clinical experience, voted against the proposal. During the meeting, he stated “we are doing harm”. His objection focused on the absence of data and the known vulnerability of newborns in the first weeks of life.
Physician Jason Goldman, serving as the ACIP liaison for the American College of Physicians, reinforced these concerns. He said the decision “will only endanger children”. The two-day meeting was marked by disorder, with several newly appointed members questioning established vaccine safety findings despite decades of consistent evidence.
More research on related medical risks appears in this report.
José Romero, global policies and the evidence base
Claims during the meeting suggested that the United States is an outlier for offering universal newborn hepatitis B vaccination. Data presented contradicted this narrative. Most countries around the world follow a similar universal approach. Several European nations vaccinate only infants of hepatitis B-positive mothers, yet they maintain higher screening coverage and universal healthcare access.
In the United States, universal vaccination functions as a safety net. Up to 18 percent of pregnant people do not receive hepatitis B testing during pregnancy. Around 2 percent receive no prenatal care at all, creating gaps that screening-based strategies cannot fully close.
On December 2, the University of Minnesota’s Vaccine Integrity Project released a review of more than 400 studies spanning four decades. The analysis reaffirmed both the severity of neonatal hepatitis B and the safety and effectiveness of the birth dose.
José Romero, former ACIP chair and current member of the American Academy of Pediatrics’ Committee on Infectious Diseases, summarized the findings. He stated “The science is unequivocal: Hepatitis B remains a real and serious risk to infants” and added that the vaccine is “one of the most important tools we have for protecting newborns”.
Romero warned that delaying the birth dose leaves newborns unprotected during a critical exposure window. A broader exploration of public-health factors is available więcej tutaj.
Hepatitis B risk in U.S. households and the role of early immunization
Newborn exposure does not occur solely through mothers. Other household members or caregivers may transmit hepatitis B through trace amounts of blood. Approximately 2 million Americans are estimated to have hepatitis B, and around half do not know they are infected.
The virus is highly contagious and can remain viable on surfaces for more than seven days. Because of these characteristics, universal newborn vaccination provides protection regardless of maternal testing accuracy or household conditions.
Infants face the highest risk of severe health consequences. Approximately 90 percent of infected infants develop chronic hepatitis B, a lifelong condition that damages the liver and increases the risk of liver cancer. One in four children with chronic infection dies prematurely from complications of the disease.
Before universal vaccination was adopted in 1991, immunization strategies targeting only high-risk groups failed to reduce infection rates. By 2018, recommendations required administering the vaccine within 24 hours of birth. As a result, cases among infants fell by 99 percent, declining from about 16,000 annually in the early 1990s to fewer than 20 perinatal infections per year.
Su Wang and the consequences of delayed protection
Physician Su Wang, who lives with chronic hepatitis B, shared her experiences during the ACIP meeting. She was born before the vaccine became available and suspects she contracted the infection from a grandparent who cared for her as an infant. She discovered her condition only in college, when she tried to donate blood.
Chronic hepatitis B can remain asymptomatic for decades. Wang explained that confirming maternal test results and identifying hepatitis B-positive family members is often complex. She spent years piecing together her medical history and only recently learned that her grandfather died of liver cancer.
“There are a lot of complex logistics in coordinating hepatitis B care,” Wang said. She emphasized that universal newborn vaccination is essential because future exposure risks cannot be predicted.
Her testimony underscored a central conclusion expressed throughout the ACIP meeting: delaying the birth dose removes a proven layer of protection and exposes newborns to preventable harm.
Source: Science News
FAQ
Why did ACIP change the hepatitis B birth-dose recommendation?
ACIP voted 8–3 to limit the birth dose to infants of hepatitis B-positive mothers, despite no new supporting data.
Does delaying the first vaccine dose increase risk?
Yes, newborns face the highest danger of severe hepatitis B complications during early life without immediate protection.
How common is universal newborn hepatitis B vaccination globally?
Most countries follow similar universal newborn vaccination policies, contradicting claims that the United States is an outlier.
Why is universal vaccination important in the United States?
Up to 18 percent of pregnant individuals are not tested for hepatitis B, and 2 percent receive no prenatal care, leaving gaps in screening.
What are the consequences of hepatitis B infection in infants?
Around 90 percent of infected infants develop chronic hepatitis B, and one in four dies prematurely from related complications.
How much did hepatitis B cases drop after introducing universal vaccination?
Infection rates in infants fell by 99 percent, from roughly 16,000 cases annually to fewer than 20 per year.
Can household members transmit hepatitis B to newborns?
Yes, the virus can spread through tiny amounts of blood and survive on surfaces for more than a week.
What experience did physician Su Wang share?
She believes she contracted hepatitis B in infancy from a family member and learned of her infection only in college.